the effect of emdogain on peri-implant mucosal inflammation (PIMI)

Not Applicable

• Conditions: peri-implamtitis(complications of dental implant).; Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts

• Registration Number: IRCT2013060113543N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Adults aged 18 or over years; PIMI with Implant Success Index (ISI) III,IV (according to KadkhodazadehM, Amid R classification ) defined as presence of BOP, without soft tissue recession with radiographic bone loss = 2mm, Pocket depth=4mm ; Implant in function for = 1 year
Exclusion criteria: Uncontrolled systemic diseases; Smoking; Active periodontal disease; Pregnancy and lactation; Radiation therapy; Drug and alcohol abuse; Consumption of systemic antibiotics in the late 1 month; Long-term use of any drug affects periodontal tissue conditions (e.g. non-steroidal anti-inflammatory drugs, anti-consultants, calcium channel blockers,bisphosphonates,...); Treatment intervention for PIMI in the late 3 months; Need for bacterial prophylaxis with systemic antibiotics; Infectios disease such as AIDS, hepatitis, and tuberculosis

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BOP. Timepoint: 0,2,4,14 week. Method of measurement: probe.

Secondary Outcome Measures

Name	Time	Method
Pocket depth. Timepoint: 0,2,4,14w. Method of measurement: probe.;IL-6 , IL-17. Timepoint: 0,2,4,14 WEEK. Method of measurement: ELISA.